Search

Displaying results 4121 - 4130 of 7455 in total
  1. Drug

    Artefenomel

    go.drugbank.com/drugs/DB11809
    Investigational

    Artefenomel has been investigated for the treatment of Malaria.

  2. Drug

    Lupeol

    go.drugbank.com/drugs/DB12622
    Investigational

    Lupeol has been investigated for the treatment of Acne.

  3. Drug

    Veldoreotide

    go.drugbank.com/drugs/DB12777
    Investigational

    Somatoprim is under investigation for the treatment of Acromegaly.

  4. Drug

    (S)-AMPA

    go.drugbank.com/drugs/DB02057
    Experimental

    AMPA is a specific agonist for the AMPA receptor.

  5. Drug

    Denibulin

    go.drugbank.com/drugs/DB05932
    Experimental

    Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.

  6. Drug

    Abivertinib

    go.drugbank.com/drugs/DB15327
    Investigational

    [L17383] It has been investigated for use in the treatment of non-small cell lung cancer (NSCLC) and B-cell malignancies.

    Categories: Experimental Unapproved Treatments for COVID-19
  7. Drug

    Gallium maltolate

    go.drugbank.com/drugs/DB05420
    Investigational

    Gallium maltolate is Titan’s novel oral agent in development for the potential treatment of chronic bacterial infections, bone disease and cancer.

  8. Drug

    LLL-3348

    go.drugbank.com/drugs/DB05771
    Experimental

    The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.

  9. Drug

    Formebolone

    go.drugbank.com/drugs/DB01569
    IllicitInvestigational

    [A14416] Additionally, it has been patented for use in development of novel transdermal delivery systems for enhanced drug delivery. … It is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes.

  10. Drug

    AP5280

    go.drugbank.com/drugs/DB05112
    Experimental

    AP5280 is a novel N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-bound platinum (Pt) therapeutic designed to increase the therapeutic index relative to conventional, small-molecule platinum agents.